Gastrointestinal Cancer

The frontline combination of toripalimab and cisplatin/paclitaxel reached its prespecified primary end points of progression-free and overall survival in patients with advanced esophageal squamous cell carcinoma in the phase 3 JUPITER-06 trial.

The plethora of actionable targets in intrahepatic cholangiocarcinoma has created opportunities for these patients to be treated with targeted therapy.

Anita Lavery, MD, MRCP, discusses achieving safe care for patients with esophagogastric cancer during the COVID-19 pandemic.

Parissa Tabrizian, MD, discusses the rationale for examining cemiplimab in hepatocellular carcinoma.

Moores Cancer Center at UC San Diego Health is among the few clinical trial sites in the U.S. for the Pancreatic Cancer Action Network’s newly created Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer.

Zev A. Wainberg, MD, discusses the role of neoadjuvant chemotherapy in resectable pancreatic cancer, emerging approaches in locally advanced disease, the promise of PARP inhibitors in the metastatic setting, and other future research directions of interest.

Derazantinib demonstrated promising disease control when given to patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusion.

Investigators are exploring a dual HER2-targeting strategy that incorporates tucatinib into a novel combination as second-line therapy for patients with HER2-positive gastric and esophageal cancers.

The FDA has granted a breakthrough therapy designation to bemarituzumab plus modified fluoropyrimidine, leucovorin, and oxaliplatin as a frontline treatment for patients with FGFR2b–overexpressing and HER2-negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma.

Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, explains what GI oncologists can expect from FGFR treatment for advanced cholangiocarcinoma in terms of treatment responses.

Recommendations for appropriately managing patients who experience adverse events associated with FGFR treatment for advanced cholangiocarcinoma.

Siddharth Padia, MD, discusses the data that led to the March 2021 FDA approval of TheraSphere™ Yttrium-90 Glass Microspheres for use in patients with hepatocellular carcinoma.

Yoomi Lee, MD, discusses the safety profile of surufatinib and highlighted future directions for patients with pancreatic and extrapancreatic NETs.

The FDA has approved nivolumab to be combined with select types of chemotherapy for the frontline treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Although anticancer therapies that leverage T cells have commanded the most attention in the immuno-oncology era of the past decade, strategies based on natural killer cells have recently emerged as attractive approaches.

Raymond Wadlow, MD, discusses the emergence of combination chemotherapy regimens in metastatic pancreatic cancer and the promise of emerging strategies that are under exploration.

Katelyn M. Atkins, MD, PhD, discusses the role of adjuvant chemoradiation therapy in gastric cancer.

Stephen L. Chan, MD; Masatoshi Kudo, MD, PhD; and Amit Singal, MD, discuss the future treatment landscape for the management of HCC (hepatocellular carcinoma).

Stephen L. Chan, MD, comments on the use of AFP as a predictive biomarker in HCC (hepatocellular carcinoma) and the current use of ramucirumab.

Amit Singal, MD; Masatoshi Kudo, MD, PhD; and Stephen L. Chan, MD, share their personal approaches to sequencing with an anti-PD-1 antibody after first-line atezolizumab-bevacizumab in HCC (hepatocellular carcinoma).

Significant tumor necrosis was observed in 20% of patients with resectable hepatocellular carcinoma who received neoadjuvant treatment with cemiplimab-rwlc.

The majority of independently adjudicated interstitial lung disease cases associated with fam-trastuzumab deruxtecan-nxki were low grade and occurred within the first 12 months of treatment, with lower risk of developing the effect observed in patients who were on the drug for longer than 1 year.

Atezolizumab elicited durable clinical activity irrespective of microsatellite instability status in patients with advanced solid tumors with a tumor mutational burden of more than 16 mutations per megabase.

R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, comments on the rationale for treating patients with advanced cholangiocarcinoma with an FGFR inhibitor.

The value of early molecular testing in cholangiocarcinoma and importance of promoting its role to both patients and GI oncologists.